20.485  -0.065 (-0.32%)		10-24 14:56
Open: 20.75 High: 20.77 Volume: 257,296		Pre. Close: 20.55 Low: 20.37 Market Cap: 1,213(M)

Short term
Mid term
Targets	6-month :	26.18	1-year :	30.58
Resists	First :	22.41	Second :	26.18
Pivot price	20.89
Supports	First :	19.86	Second :	18.28
MAs	MA(5) :	20.96	MA(20) :	20.67
	MA(100) :	20.43	MA(250) :	21.14
MACD	MACD :	0.2	Signal :	0.3
%K %D	K(14,3) :	41.1	D(3) :	52.8
RSI	RSI(14): 49.7
52-week	High :	29.78	Low :	13.3

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ELVN ] has closed above bottom band by 34.4%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	21.18 - 21.29	21.29 - 21.4
Low:	19.95 - 20.1	20.1 - 20.24
Close:	20.33 - 20.55	20.55 - 20.75

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Thu, 23 Oct 2025
Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term Momentum - Yahoo Finance

Sun, 19 Oct 2025
Enliven Therapeutics (ELVN): Examining Valuation After Recent Share Price Momentum - simplywall.st

Fri, 17 Oct 2025
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Investor Outlook on a Potential 89.66% Upside - DirectorsTalk Interviews

Sat, 11 Oct 2025
Enliven Therapeutics (ELVN): Evaluating Valuation After Recent Share Price Momentum - simplywall.st

Fri, 03 Oct 2025
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Potential Upside of Over 107% Captures Investor Attention - DirectorsTalk Interviews

Fri, 12 Sep 2025
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	59 (M)
Shares Float	36 (M)
Held by Insiders	8.2 (%)
Held by Institutions	104.3 (%)
Shares Short	5,700 (K)
Shares Short P.Month	4,890 (K)

EPS	-2
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-17.2 %
Return on Equity (ttm)	-25.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.93
Qtrly Earnings Growth	0 %
Operating Cash Flow	-71 (M)
Levered Free Cash Flow	-53 (M)

PE Ratio	-10.31
PEG Ratio	0
Price to Book value	2.48
Price to Sales	0
Price to Cash Flow	-17.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.